Pharmafile Logo

Ryvu Therapeutics

Ryvu Therapeutics Announces Three Abstracts on Romaciclib (RVU120) and One Abstract on Dapolsertib (MEN1703) at the 2025 ASH Annual Meeting

Romaciclib continues to show efficacy in AML: Data from the Phase II RIVER-81 trial suggest that romaciclib restores sensitivity to venetoclax in resistant AML, inducing complete remissions with a favorable safety profile Clinical activity in myelofibrosis (MF): Interim results from the Phase II POTAMI-61 study indicate clinically meaningful spleen volume and symptom reductions, supporting romaciclib’s potential role in the post-JAK inhibitor setting. Erythroid response in LR-MDS: In the romaciclib’s Phase II REMARK study, one heavily pretreated patient achieved a major erythroid response Dapolsertib continues evaluation in aggressive...

Ryvu Therapeutics Presents RVU305 (PRMT5i) and ONCO Prime Platform Data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates strong and selective antitumor efficacy in MTAP-deleted glioblastoma models, with confirmed brain exposure and a favorable safety profile supporting IND/CTA-enabling studies ONCO Prime - an integrated synthetic lethality discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics – uncovers the identification of novel targets across...

Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland

Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients Clinical programs planned to be included in the agreement span multiple solid tumor types, including lung,...

Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting

KRAS-specific synthetic lethal targets identified through Ryvu's ONCO Prime platform show promising potential for new therapeutic options for colorectal cancer (CRC) patients RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant tumor growth inhibition in MTAP-deleted cancer models and enhances antitumor responses when combined with an anti-PD-1 antibody. 26 March 2025 -- Kraków, Poland...
https://ryvu.com/
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

+48 12 314 02 00